Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Anika Therapeutics (ANIK) over the last 14 years, with Dec 2024 value amounting to $2.1 million.

  • Anika Therapeutics' Gains from Investment Securities fell 40.91% to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 113.97%. This contributed to the annual value of $2.1 million for FY2024, which is 15.24% up from last year.
  • Anika Therapeutics' Gains from Investment Securities amounted to $2.1 million in FY2024, which was up 15.24% from $1.8 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Gains from Investment Securities registered a high of $2.1 million during FY2024, and its lowest value of $896,819 during FY2020.
  • Its 3-year average for Gains from Investment Securities is $1.8 million, with a median of $1.8 million in 2023.
  • In the last 5 years, Anika Therapeutics' Gains from Investment Securities crashed by 90.31% in 2020 and then skyrocketed by 31.13% in 2021.
  • Anika Therapeutics' Gains from Investment Securities (Yearly) stood at $896,819 in 2020, then skyrocketed by 31.13% to $1.2 million in 2021, then spiked by 30.16% to $1.5 million in 2022, then climbed by 18.42% to $1.8 million in 2023, then increased by 15.24% to $2.1 million in 2024.